Chelsea Therapeutics International 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 26, 2010
CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
(Exact name of registrant as specified in its charter)
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Item 1.01. Entry into a Material Definitive Agreement.
On February 26, 2010, we entered into a placement agency agreement with Leerink Swann LLC and Needham & Company, LLC relating to a proposed registered direct offering of up to 6,700,000 units, with each unit consisting of (i) one share of our common stock, par value $0.0001 per share and (ii) a warrant to purchase 0.35 shares of common stock. The per unit purchase price is $2.72. The units are to be sold pursuant to subscription agreements to be entered into by and between the investor signatories and us. A copy of the placement agency agreement is filed as Exhibit 1.1 to this report and a form of the subscription agreement is filed as Exhibit 10.15 to this report and each is incorporated herein by reference.
In the aggregate, we would issue up to 6,700,000 shares of common stock and warrants to purchase up to 2,345,000 shares of common stock pursuant to the terms of the placement agency agreement and the related subscription agreements. The warrants to be issued to each investor would generally be exercisable for a period of three years from the date of issuance beginning six months after the date of issuance, and would carry an exercise price of $2.79 per share, which is equal to the consolidated closing bid price of the common stock on February 25, 2010 as reported by Nasdaq.
Leerink Swann is acting as lead placement agent and Needham & Company is acting as co-placement agent for the offering. The placement agents will receive an aggregate placement agents fee equal to $1,000,000. We estimate the offering will result in gross proceeds of approximately $18.2 million, before deducting the placement agents fees and offering expenses.
The financing was led by funds affiliated with Venrock Associates.
The shares and the warrants included in the units, and the shares of common stock issuable upon exercise of the warrants, are being offered pursuant to our registration statement on Form S-3 (Registration Statement No. 333-161236), as declared effective by the Securities and Exchange Commission on August 20, 2009. The opinion of Wyrick Robbins Yates & Ponton LLP regarding the securities to be issued is filed as Exhibit 5.1 to this report.
The closing of the sale and issuance of the units is expected to take place on or about March 5, 2010, subject to the satisfaction of customary closing conditions.
The foregoing is only a brief description of the material terms of the placement agency agreement, the warrants and the subscription agreements, does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the placement agent agreement, the form of warrant and the form of subscription agreement, respectively, that are filed as Exhibits 1.1, 4.1 and 10.15, respectively, to this Current Report on Form 8-K and incorporated by reference herein.
Item 8.01. Other Events.
On February 26, 2010, we issued a press release announcing the proposed registered direct offering described in Item 1.01 of this Current Report. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.